Skip to main content

This job has expired

You will need to login before you can apply for a job.

Associate Scientist – AAV Vector Biology

Employer
Intellia Therapeutics
Location
Cambridge, MA
Start date
Sep 15, 2022

View more

Discipline
Science/R&D, Biology, Biotechnology
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Genetown, Best Places to Work

Job Details

Why Join Intellia?

Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done.

We wantall ofour people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together.

How you will Achieve More with Intellia:

As an Associate Scientist in the AAV Vector Biology group, you will help advance Intellia’s gene editing platform and pipeline. This role will apply new approaches for engineering and optimizing viral vectors for gene editing.

Key responsibilities include:

  • Design, execute and troubleshoot experiments

  • Present research findings internally and externally to cross-functional teams

  • Assist with general laboratory maintenance

  • Maintain a detailed electronic laboratory notebook

About You:

We are looking for a motivated and detail-oriented scientist with experience developing AAV vectors for gene therapy. The ideal candidate thrives on working in a fast-paced, collaborative team environment and is passionate about pioneering new gene-editing technologies to treat diseases with an unmet clinical need. Other important qualities include:

  • B.S. or M.S. in Molecular/Cell Biology, Genetics, Virology, Bioengineering or a closely related field

  • Hands-on experience with molecular biology techniques including cloning, nucleic acid purification, PCR/qPCR, microscopy, and western blotting

  • Hands-on experience with mammalian cell culture

  • Previous experience with AAV biology preferred

  • Highly organized and proven track record of problem solving

  • Strong verbal and written communication skills

Meet your future team:

The Gene Editing Platform team is an energetic and passionate group of individuals whose mission is to advance and differentiate Intellia’s platform to enable curative therapies. You will join a team with vector design and production expertise, and work closely with leaders in the field of CRISPR/Cas9 gene editing. The candidate will have many opportunities to broaden their experience with multiple cutting-edge gene therapy technologies that advance Intellia’s pipeline. The team is currently working mostly onsite to execute workflows in a wet-lab environment. Therefore, candidate must be local to Cambridge, MA or open to relocating.

Covid-19 Vaccination Policy: All Intellia employees, regardless of work location, must be fully vaccinated for COVID-19. This requirement includes a booster dose once eligible. Requests for exemption for medical or sincerely held religious beliefs will be considered.

EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

Company

Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with often debilitating and life-threatening symptoms, but these disorders also significantly impact their families, friends and caregivers.
 
Our researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Jennifer Doudna, an Intellia co-founder, and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry for their pioneering work in CRISPR. We at Intellia are humbled to have a hand in making what we believe to be medical history. As a leader in this space, we take this responsibility to patients seriously.
 
We are employing a modular genome editing platform to create diverse in vivo and ex vivo pipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, we are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

Change life stories with genome editing therapies!

Stock Symbol: NTLA

TwitterInstagram

Company info
Website
Phone
(857) 285-6200
Location
40 Erie Street
Cambridge
Massachusetts
02139
United States

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert